Error loading player: No playable sources found

Expert Roundtable

Date
June 24, 2020

Expert Roundtable

Expert Roundtable: How do we realize the full potential for Small Molecule in the new decade? Panel discussion with experts in the area of small molecule continuous manufacturing will discuss the technical, regulatory, and business hurdles for continuous manufacturing. This session will highlight CM as a continuum from E2E to hybrid approaches, including the need for "batch steps" for some products, requirement differences which can be a hindrance to global implementation of advanced technologies enabled by CM such as PAT, RTRT, and modeling; and why E2E CM may or may not be the optimal solution.        

  • Malcolm Berry, PhD, CEO & Founder MB
    Chemistry Consulting, Ltd.    
  • Sharmista Chatterjee, PhD, Division Director OPMA,
    OPQ/CDER  
  • Gabriella Dahlgren, PhD, Manager, Strategy Deployment
    Janssen Supply Group LLC      
  • Elizabeth Grieco, Director Vertex  
  • Michael O’Brien, PhD, Founder and President NGT
    BioPharma Consultants

Leader/Speakers

Speaker Image for Michael O'Brien
President & CEO, NGT BioPharma Consutlants
Speaker Image for Gabriella Dahlgren
Manager, Strategy Deployment and Excellence, PQM, Janssen Supply Group

Speakers

Speaker Image for Malcolm Berry
Continuous Chemistry Team Manager, MB Chemistry Consulting, Ltd.
Speaker Image for Sharmista Chatterjee
Division Director, FDA, OPMA

Related Products

Thumbnail for Advances in Continuous Manufacturing for Small Molecule
Advances in Continuous Manufacturing for Small Molecule
ADVANCES IN CONTINUOUS MANUFACTURING FOR SMALL MOLECULE
Thumbnail for Transportable, Small Footprint Biopharmaceutical Manufacturing Facilities: A Regulatory Perspective
Transportable, Small Footprint Biopharmaceutical Manufacturing Facilities: A Regulatory Perspective
Today’s manufacturing platforms and associated analytics are smaller, lighter, and significantly more modular versus their predecessors…
Thumbnail for Concurrent Session: Transportable, Small Footprint Biopharmaceutical Manufacturing Facilities: A Regulatory Perspective 
Concurrent Session: Transportable, Small Footprint Biopharmaceutical Manufacturing Facilities: A Regulatory Perspective 
Concurrent Session: Transportable, Small Footprint Biopharmaceutical Manufacturing Facilities: A Regulatory Perspective | Today’s manufacturing platforms and associated analytics are smaller, lighter, and significantly more modular versus their predecessors…
Thumbnail for Modular Facility
Modular Facility
This session will explore novel ways to reduce project time lines and demonstrate how PODular manufacturing will increase facility flexibility to meet potential future changing business needs…